Bio-Techne agreed to acquire 100% ownership of Cliniqa, which specializes in the manufacture and commercialization of quality controls and calibrators as well as bulk reagents used in the clinical diagnostic market. Its controls and reagents are used in a wide variety of diagnostic tests for such pathologies as cardiac disease diabetes, cancer, immunological disorders, therapeutic drug monitoring, urine analysis and toxicology.
Cliniqa was founded in 1974, is based in San Marcos, CA, and has approximately 75 employees.
“I am very pleased with this acquisition as it strengthens not only our clinical controls product portfolio, but also our reach into the IVD/clinical diagnostics segment, as well as our management team,” said Charles Kummeth, president and CEO of Bio-Techne. “The addition of Cliniqa adds important capabilities to Bio-Techne as we continue to solidify our market presence and expand our business into key adjacent markets, such as immunodiagnostics.”
Cliniqa’s CEO, Kevin Gould, and other members of the Cliniqa leadership team will remain in place following the closing